{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T03:18:19Z","timestamp":1761707899897,"version":"3.32.0"},"reference-count":67,"publisher":"SAGE Publications","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cutan Med Surg"],"published-print":{"date-parts":[[2005,12]]},"DOI":"10.1007\/s10227-005-0110-7","type":"journal-article","created":{"date-parts":[[2006,5,12]],"date-time":"2006-05-12T16:06:11Z","timestamp":1147449971000},"page":"296-302","source":"Crossref","is-referenced-by-count":47,"title":["Off-Label Dermatologic Uses of Anti-TNF-a Therapies"],"prefix":"10.1177","volume":"9","author":[{"given":"Andrew F.","family":"Alexis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruce E.","family":"Strober","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"179","published-online":{"date-parts":[[2006,5,25]]},"reference":[{"issue":"11","key":"110_CR1","first-page":"1590","volume":"3","author":"G Girolomoni","year":"2002","unstructured":"Girolomoni G, et al. Targeting tumor necrosis factor-alpha as a potential therapy in inflammatory skin diseases. Curr Opin Investig Drugs 2002; 3(11):1590\u20131595","journal-title":"Curr Opin Investig Drugs"},{"issue":"5","key":"110_CR2","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2165\/00002018-200427050-00003","volume":"27","author":"D Khanna","year":"2004","unstructured":"Khanna D, McMahon M, Furst DE. Safety of tumour necrosis factor-alpha antagonists. Drug Saf 2004; 27(5):307\u2013324","journal-title":"Drug Saf"},{"issue":"6 Suppl 28","key":"110_CR3","first-page":"S122","volume":"20","author":"C Antoni","year":"2002","unstructured":"Antoni C, Manger B. Infliximab for psoriasis and psoriatic arthritis. Clin Exp Rheumatol 2002; 20(6 Suppl 28):S122\u2013S125","journal-title":"Clin Exp Rheumatol"},{"issue":"9271","key":"110_CR4","doi-asserted-by":"crossref","first-page":"1842","DOI":"10.1016\/S0140-6736(00)04954-0","volume":"357","author":"U Chaudhari","year":"2001","unstructured":"Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001; 357(9271):1842\u20131847","journal-title":"Lancet"},{"issue":"5","key":"110_CR5","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1177\/120347540300700503","volume":"7","author":"A Drosou","year":"2003","unstructured":"Drosou A, Kirsner RS, Welsh E, et al. Use of infliximab, an anti-tumor necrosis alpha antibody, for inflammatory dermatoses. J Cutan Med Surg 2003; 7(5):382\u2013386","journal-title":"J Cutan Med Surg"},{"issue":"15","key":"110_CR6","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1056\/NEJMoa011110","volume":"345","author":"J Keane","year":"2001","unstructured":"Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345(15):1098\u20131104","journal-title":"N Engl J Med"},{"issue":"2 Suppl","key":"110_CR7","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1016\/mjd.2003.554","volume":"49","author":"B Goffe","year":"2003","unstructured":"Goffe B, Cather JC. Etanercept: an overview. J Am Acad Dermatol 2003; 49(2 Suppl):S105\u2013S111","journal-title":"J Am Acad Dermatol"},{"issue":"7","key":"110_CR8","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1016\/S0016-5085(03)00382-2","volume":"124","author":"JM Brande Van den","year":"2003","unstructured":"Van den Brande JM, Braat H, van den Brink GR, et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn\u2019s disease. Gastroenterology 2003; 124(7):1774\u20131785","journal-title":"Gastroenterology"},{"issue":"4","key":"110_CR9","first-page":"375","volume":"2","author":"N Scheinfeld","year":"2003","unstructured":"Scheinfeld N. Adalimumab (HUMIRA): a review. J Drugs Dermatol 2003; 2(4):375\u2013377","journal-title":"J Drugs Dermatol"},{"issue":"17","key":"110_CR10","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1056\/NEJM199704243361706","volume":"336","author":"LS Newman","year":"1997","unstructured":"Newman LS, Rose CS, Maier LA. Sarcoidosis. N Engl J Med 1997; 336(17):1224\u20131234","journal-title":"N Engl J Med"},{"issue":"2","key":"110_CR11","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1067\/mjd.2003.228","volume":"48","author":"L Mallbris","year":"2003","unstructured":"Mallbris L, Ljungberg A, Hedblad MA, et al. Progressive cutaneous sarcoidosis responding to anti-tumor necrosis factor-alpha therapy. J Am Acad Dermatol 2003; 48(2):290\u2013293","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"110_CR12","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1378\/chest.124.1.177","volume":"124","author":"JP Utz","year":"2003","unstructured":"Utz JP, Limper AH, Kalra S, et al. Etanercept for the treatment of stage II and III progressive pulmonary sarcoidosis. Chest 2003; 124(1):177\u2013185","journal-title":"Chest"},{"issue":"9363","key":"110_CR13","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/S0140-6736(03)12888-7","volume":"361","author":"RP Baughman","year":"2003","unstructured":"Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet 2003; 361(9363):1111\u20131118","journal-title":"Lancet"},{"issue":"1","key":"110_CR14","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/j.1365-2133.2004.05769.x","volume":"150","author":"H Haley","year":"2004","unstructured":"Haley H, Cantrell W, Smith K. Infliximab therapy for sarcoidosis (lupus pernio). Br J Dermatol 2004; 150(1):146\u2013149","journal-title":"Br J Dermatol"},{"issue":"5","key":"110_CR15","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1378\/chest.124.5.2028","volume":"124","author":"SD Roberts","year":"2003","unstructured":"Roberts SD, et al. Refractory sarcoidosis responding to infliximab. Chest 2003; 124(5):2028\u20132031","journal-title":"Chest"},{"issue":"3","key":"110_CR16","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1136\/ard.2002.004226","volume":"63","author":"C Pritchard","year":"2004","unstructured":"Pritchard C, Nadarajah K. Tumour necrosis factor alpha inhibitor treatment for sarcoidosis refractory to conventional treatments: a report of five patients. Ann Rheum Dis 2004; 63(3):318\u2013320","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"110_CR17","first-page":"70","volume":"18","author":"RP Baughman","year":"2001","unstructured":"Baughman RP, Lower EE. Infliximab for refractory sarcoidosis. Sarcoidosis Vasc Diffuse Lung Dis 2001; 18(1):70\u201374","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"issue":"8","key":"110_CR18","first-page":"1864","volume":"30","author":"D Khanna","year":"2003","unstructured":"Khanna D, Liebling MR, Louie JS. Etanercept ameliorates sarcoidosis arthritis and skin disease. J Rheumatol 2003; 30(8):1864\u20131867","journal-title":"J Rheumatol"},{"key":"110_CR19","first-page":"1140","volume-title":"Fitzpatrick\u2019s dermatology in general medicine","author":"K Wolff","year":"1999","unstructured":"Wolff K, Stingl G. Pyoderma Gangrenosum. In: Freedberg IMea, (editor.) Fitzpatrick\u2019s dermatology in general medicine, 5th ed. New York, McGraw-Hill Health Professions Division, 1999; 1140\u20131148","edition":"5"},{"issue":"8","key":"110_CR20","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1111\/j.1572-0241.2003.07581.x","volume":"98","author":"M Regueiro","year":"2003","unstructured":"Regueiro M, Valentine J, Plevy S, et al. Infliximab for treatment of pyoderma gangrenosum associated with inflammatory bowel disease. Am J Gastroenterol 2003; 98(8):1821\u20131826","journal-title":"Am J Gastroenterol"},{"key":"110_CR21","doi-asserted-by":"crossref","unstructured":"Kaufman I, Caspi D, Yeshurun D, et al. The effect of infliximab on extraintestinal manifestations of Crohn\u2019s disease. Rheumatol Int 2004","DOI":"10.1007\/s00296-004-0467-8"},{"issue":"2","key":"110_CR22","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1111\/j.1365-2133.2003.05760.x","volume":"150","author":"L Jenne","year":"2004","unstructured":"Jenne L, Sauter B, Thumann P, et al. Successful treatment of therapy-resistant chronic vegetating pyoderma gangrenosum with infliximab (chimeric antitumour necrosis factor antibody). Br J Dermatol 2004; 150(2):380\u2013382","journal-title":"Br J Dermatol"},{"issue":"6","key":"110_CR23","doi-asserted-by":"crossref","first-page":"420","DOI":"10.4321\/S1130-01082004000600008","volume":"96","author":"A Lopez San Roman","year":"2004","unstructured":"Lopez San Roman A, Bermejo F, Aldanondo I, et al. Pyoderma gangrenosum associated with ulcerative colitis: response to infliximab. Rev Esp Enferm Dig 2004; 96(6):420\u2013424","journal-title":"Rev Esp Enferm Dig"},{"issue":"2","key":"110_CR24","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1111\/j.1365-2230.2004.01470.x","volume":"29","author":"M Singh","year":"2004","unstructured":"Singh M, Andrew SM, Lear JT. Infliximab as a treatment for recalcitrant pyoderma gangrenosum. Clin Exp Dermatol 2004; 29(2):196\u2013197","journal-title":"Clin Exp Dermatol"},{"issue":"3","key":"110_CR25","first-page":"258","volume":"13","author":"A Zaccagna","year":"2003","unstructured":"Zaccagna A, Bertone A, Puiatti P, et al. Anti-tumor necrosis factor alpha monoclonal antibody (infliximab) for the treatment of Pyoderma gangrenosum associated with Crohn\u2019s disease. Eur J Dermatol 2003; 13(3):258\u2013260","journal-title":"Eur J Dermatol"},{"issue":"3","key":"110_CR26","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1159\/000065860","volume":"205","author":"F Grange","year":"2002","unstructured":"Grange F, Djilali-Bouzina F, Weiss AM, et al. Corticosteroid-resistant pyoderma gangrenosum associated with Crohn\u2019s disease: rapid cure with infliximab. Dermatology 2002; 205(3):278\u2013280","journal-title":"Dermatology"},{"issue":"7","key":"110_CR27","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1080\/gas.37.7.863.865","volume":"37","author":"JK Triantafillidis","year":"2002","unstructured":"Triantafillidis JK, et al. Favorable response to infliximab treatment in a patient with active Crohn disease and pyoderma gangrenosum. Scand J Gastroenterol 2002; 37(7):863\u2013865","journal-title":"Scand J Gastroenterol"},{"issue":"8","key":"110_CR28","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1097\/00042737-200208000-00021","volume":"14","author":"M Romero-Gomez","year":"2002","unstructured":"Romero-Gomez M, Sanchez-Munoz D. Infliximab induces remission of pyoderma gangrenosum. Eur J Gastroenterol Hepatol 2002; 14(8):907","journal-title":"Eur J Gastroenterol Hepatol"},{"issue":"5","key":"110_CR29","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1097\/00005176-200205000-00016","volume":"34","author":"LA Batres","year":"2002","unstructured":"Batres LA, Mamula P, Baldassano RN. Resolution of severe peristomal pyoderma gangrenosum with infliximab in a child with Crohn disease. J Pediatr Gastroenterol Nutr 2002; 34(5):558\u2013560","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"2","key":"110_CR30","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1097\/00005176-200308000-00013","volume":"37","author":"S Kugathasan","year":"2003","unstructured":"Kugathasan S, Miranda A, Nocton J, et al. Dermatologic manifestations of Crohn disease in children: response to infliximab. J Pediatr Gastroenterol Nutr 2003; 37(2):150\u2013154","journal-title":"J Pediatr Gastroenterol Nutr"},{"issue":"4","key":"110_CR31","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1046\/j.1365-2133.2003.05294.x","volume":"148","author":"D Mimouni","year":"2003","unstructured":"Mimouni D, et al. Infliximab for peristomal pyoderma gangrenosum. Br J Dermatol 2003; 148(4):813\u2013816","journal-title":"Br J Dermatol"},{"issue":"9","key":"110_CR32","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1080\/003655202320378338","volume":"37","author":"T Ljung","year":"2002","unstructured":"Ljung T, Staun M, Grove O, et al. Pyoderma gangrenosum associated with crohn disease: effect of TNF-alpha blockade with infliximab. Scand J Gastroenterol 2002; 37(9):1108\u20131110","journal-title":"Scand J Gastroenterol"},{"issue":"7","key":"110_CR33","first-page":"930","volume":"137","author":"MH Tan","year":"2001","unstructured":"Tan MH, Gordon M, Lebwohl O, et al. Improvement of Pyoderma gangrenosum and psoriasis associated with Crohn disease with anti-tumor necrosis factor alpha monoclonal antibody. Arch Dermatol 2001; 137(7):930\u2013933","journal-title":"Arch Dermatol"},{"issue":"12","key":"110_CR34","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1001\/jama.284.12.1546","volume":"284","author":"AP Hughes","year":"2000","unstructured":"Hughes AP, Jackson JM, Callen JP. Clinical features and treatment of peristomal pyoderma gangrenosum. JAMA 2000; 284(12):1546\u20131548","journal-title":"JAMA"},{"issue":"5","key":"110_CR35","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1001\/archsurg.135.5.564","volume":"135","author":"DG Sheldon","year":"2000","unstructured":"Sheldon DG, et al. Twenty cases of peristomal pyoderma gangrenosum: diagnostic implications and management. Arch Surg 2000;135(5):564\u2013568; discussion 568\u2013569","journal-title":"Arch Surg"},{"issue":"2","key":"110_CR36","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1111\/j.1365-2230.2004.01681.x","volume":"30","author":"VJ Swale","year":"2005","unstructured":"Swale VJ, Saha M, Kapur N, et al. Pyoderma gangrenosum outside the context of inflammatory bowel disease treated successfully with infliximab. Clin Exp Dermatol 2005; 30(2):134\u2013136","journal-title":"Clin Exp Dermatol"},{"issue":"4","key":"110_CR37","first-page":"441","volume":"3","author":"McGowan JWt","year":"2004","unstructured":"McGowan JWt, Johnson CA, Lynn A. Treatment of pyoderma gangrenosum with etanercept. J Drugs Dermatol 2004; 3(4):441\u2013444","journal-title":"J Drugs Dermatol"},{"issue":"4","key":"110_CR38","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/j.1365-2133.1991.tb14178.x","volume":"125","author":"LS Ostlere","year":"1991","unstructured":"Ostlere LS, et al. Hidradenitis suppurativa in Crohn\u2019s disease. Br J Dermatol 1991; 125(4):384\u2013386","journal-title":"Br J Dermatol"},{"issue":"12","key":"110_CR39","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1001\/archderm.139.12.1540","volume":"139","author":"DR Adams","year":"2003","unstructured":"Adams DR, et al. Severe hidradenitis suppurativa treated with infliximab infusion. Arch Dermatol 2003; 139(12):1540\u20131542","journal-title":"Arch Dermatol"},{"issue":"8","key":"110_CR40","doi-asserted-by":"crossref","first-page":"2155","DOI":"10.1111\/j.1572-0241.2002.05950.x","volume":"97","author":"KH Katsanos","year":"2002","unstructured":"Katsanos KH, Christodoulou DK, Tsianos EV. Axillary hidradenitis suppurativa successfully treated with infliximab in a Crohn\u2019s disease patient. Am J Gastroenterol 2002; 97(8):2155\u20132156","journal-title":"Am J Gastroenterol"},{"issue":"5 Suppl","key":"110_CR41","doi-asserted-by":"crossref","first-page":"S275","DOI":"10.1016\/S0190-9622(03)01132-0","volume":"49","author":"B Lebwohl","year":"2003","unstructured":"Lebwohl B, Sapadin AN. Infliximab for the treatment of hidradenitis suppurativa. J Am Acad Dermatol 2003; 49(5 Suppl):S275\u2013S276","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"110_CR42","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/00054725-200111000-00008","volume":"7","author":"F Martinez","year":"2001","unstructured":"Martinez F, et al. Hidradenitis suppurativa and Crohn\u2019s disease: response to treatment with infliximab. Inflamm Bowel Dis 2001; 7(4):323\u2013326","journal-title":"Inflamm Bowel Dis"},{"issue":"10","key":"110_CR43","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1007\/s00535-003-1185-9","volume":"38","author":"M Roussomoustakaki","year":"2003","unstructured":"Roussomoustakaki M, Dimoulios P, Chatzicostas C, et al. Hidradenitis suppurativa associated with Crohn\u2019s disease and spondyloarthropathy: response to anti-TNF therapy. J Gastroenterol 2003; 38(10):1000\u20131004","journal-title":"J Gastroenterol"},{"issue":"1","key":"110_CR44","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1053\/sarh.2003.50022","volume":"33","author":"DG Stokes","year":"2003","unstructured":"Stokes DG, Kremer JM. Potential of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis. Semin Arthritis Rheum 2003; 33(1):1\u201318","journal-title":"Semin Arthritis Rheum"},{"issue":"1","key":"110_CR45","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00002281-200401000-00008","volume":"16","author":"S Yurdakul","year":"2004","unstructured":"Yurdakul S, Hamuryudan V, Yazici H. Behcet syndrome. Curr Opin Rheumatol 2004; 16(1):38\u201342","journal-title":"Curr Opin Rheumatol"},{"key":"110_CR46","doi-asserted-by":"crossref","DOI":"10.1007\/b100540","volume-title":"Adamantiades-Beh\u00f0cet\u2019s disease","author":"CC Zouboulis","year":"2003","unstructured":"Zouboulis CC. Adamantiades-Beh\u00f0cet\u2019s disease. New York: Kluwer, 2003"},{"issue":"Suppl 2","key":"110_CR47","doi-asserted-by":"crossref","first-page":"ii79","DOI":"10.1136\/ard.2004.028498","volume":"63","author":"EC Keystone","year":"2004","unstructured":"Keystone EC. The utility of tumour necrosis factor blockade in orphan diseases. Ann Rheum Dis 2004; 63 (Suppl 2):ii79\u2013ii83","journal-title":"Ann Rheum Dis"},{"key":"110_CR48","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/0-306-48382-3_111","volume":"528","author":"CG Katsiari","year":"2003","unstructured":"Katsiari CG, Theodossiadis PG, Kaklamanis PG, et al. Successful long-term treatment of refractory Adamantiades-Behcet\u2019s disease (ABD) with infliximab: report of two patients. Adv Exp Med Biol 2003; 528:551\u2013555","journal-title":"Adv Exp Med Biol"},{"issue":"4","key":"110_CR49","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1093\/rheumatology\/40.4.473","volume":"40","author":"LP Robertson","year":"2001","unstructured":"Robertson LP, Hickling P. Treatment of recalcitrant orogenital ulceration of Behcet\u2019s syndrome with infliximab. Rheumatology (Oxford) 2001; 40(4):473\u2013474","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"110_CR50","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1136\/ard.61.3.283-a","volume":"61","author":"M Rozenbaum","year":"2002","unstructured":"Rozenbaum M, Rosner I, Portnoy E. Remission of Behcet\u2019s syndrome with TNFalpha blocking treatment. Ann Rheum Dis 2002; 61(3):283\u2013284","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"110_CR51","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/1471-2474-4-19","volume":"4","author":"S Gulli","year":"2003","unstructured":"Gulli S, Arrigo C, Bocchino L, et al. Remission of Behcet\u2019s disease with anti-tumor necrosis factor monoclonal antibody therapy: a case report. BMC Musculoskelet Disord 2003; 4(1):19","journal-title":"BMC Musculoskelet Disord"},{"issue":"6","key":"110_CR52","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1136\/ard.60.6.637","volume":"60","author":"PH Goossens","year":"2001","unstructured":"Goossens PH, Verburg RJ, Breedveld FC. Remission of Behcet\u2019s syndrome with tumour necrosis factor alpha blocking therapy. Ann Rheum Dis 2001; 60(6):637","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"110_CR53","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1136\/ard.2003.010975","volume":"63","author":"G Haugeberg","year":"2004","unstructured":"Haugeberg G, Velken M, Johnsen V. Successful treatment of genital ulcers with infliximab in Behcet\u2019s disease. Ann Rheum Dis 2004; 63(6):744\u2013745","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"110_CR54","first-page":"98","volume":"32","author":"M Melikoglu","year":"2005","unstructured":"Melikoglu M, Fresko I, Mat C, et al. Short-term trial of etanercept in Behcet\u2019s disease: a double blind, placebo controlled study. J Rheumatol 2005; 32(1):98\u2013105","journal-title":"J Rheumatol"},{"issue":"8","key":"110_CR55","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1001\/archderm.140.8.919","volume":"140","author":"BT Kovach","year":"2004","unstructured":"Kovach BT, et al. Treatment of multicentric reticulohistiocytosis with etanercept. Arch Dermatol 2004; 140(8):919\u2013921","journal-title":"Arch Dermatol"},{"issue":"3","key":"110_CR56","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/art.10781","volume":"48","author":"C Matejicka","year":"2003","unstructured":"Matejicka C, Morgan GJ, Schlegelmilch JG. Multicentric reticulohistiocytosis treated successfully with an anti-tumor necrosis factor agent: comment on the article by Gorman et al. Arthritis Rheum 2003;48(3):864\u2013866","journal-title":"Arthritis Rheum"},{"issue":"1","key":"110_CR57","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1067\/mjd.2001.119100","volume":"46","author":"C Sacher","year":"2002","unstructured":"Sacher C, Rubbert A, Konig C, et al. Treatment of recalcitrant cicatricial pemphigoid with the tumor necrosis factor alpha antagonist etanercept. J Am Acad Dermatol 2002; 46(1):113\u2013115","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"110_CR58","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1001\/archderm.139.10.1259","volume":"139","author":"ND Robinson","year":"2003","unstructured":"Robinson ND, Guitart J. Recalcitrant, recurrent aphthous stomatitis treated with etanercept. Arch Dermatol 2003; 139(10):1259\u20131262","journal-title":"Arch Dermatol"},{"issue":"12","key":"110_CR59","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1001\/archderm.137.12.1571","volume":"137","author":"C Voigtlander","year":"2001","unstructured":"Voigtlander C, et al. Infliximab (anti-tumor necrosis factor alpha antibody): a novel, highly effective treatment of recalcitrant subcorneal pustular dermatosis (Sneddon-Wilkinson disease). Arch Dermatol 2001; 137(12):1571\u20131574","journal-title":"Arch Dermatol"},{"issue":"1","key":"110_CR60","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1159\/000070852","volume":"50","author":"GJ Hengstman","year":"2003","unstructured":"Hengstman GJ, van den Hoogen FH, Barrera P, et al. Successful treatment of dermatomyositis and polymyositis with anti-tumor-necrosis-factor-alpha: preliminary observations. Eur Neurol 2003; 50(1):10\u201315","journal-title":"Eur Neurol"},{"issue":"Suppl.","key":"110_CR61","first-page":"S193","volume":"43","author":"C Saadeyh","year":"2000","unstructured":"Saadeyh C. Etanercept is effective in the treatment of polymyositis\/dermatomyositis which is refractory to conventional therapy.[abstract]. Arthritis Rheum 2000; 43(Suppl.):S193","journal-title":"Arthritis Rheum"},{"issue":"12","key":"110_CR62","first-page":"2525","volume":"29","author":"MA Fitzcharles","year":"2002","unstructured":"Fitzcharles MA, Clayton D, Menard HA. The use of infliximab in academic rheumatology practice: an audit of early clinical experience. J Rheumatol 2002; 29(12):2525\u20132530","journal-title":"J Rheumatol"},{"issue":"Suppl","key":"110_CR63","first-page":"s392","volume":"43","author":"M Ellman","year":"2000","unstructured":"Ellman M. Etanerceot as treatment for diffuse scleroderma: a pilot study [abstract]. Arthritis Rheum 2000;43(Suppl):s392","journal-title":"Arthritis Rheum"},{"issue":"1","key":"110_CR64","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1001\/archderm.138.1.99","volume":"138","author":"AN Sapadin","year":"2002","unstructured":"Sapadin AN, Fleischmajer R. Treatment of scleroderma. Arch Dermatol 2002; 138(1):99\u2013105","journal-title":"Arch Dermatol"},{"issue":"4","key":"110_CR65","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1136\/ard.61.4.375","volume":"61","author":"I Olivieri","year":"2002","unstructured":"Olivieri I, Padula A, Ciancio G, et al. Successful treatment of SAPHO syndrome with infliximab: report of two cases. Ann Rheum Dis 2002; 61(4):375\u2013376","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"110_CR66","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1002\/art.10539","volume":"46","author":"AD Wagner","year":"2002","unstructured":"Wagner AD, Andresen J, Jendro MC, et al. Sustained response to tumor necrosis factor alpha-blocking agents in two patients with SAPHO syndrome. Arthritis Rheum 2002; 46(7):1965\u20131968","journal-title":"Arthritis Rheum"},{"key":"110_CR67","doi-asserted-by":"crossref","unstructured":"Etanercept plus standard therapy for Wegener\u2019s granulomatosis. N Engl J Med 2005; 352(4):351\u2013361","DOI":"10.1056\/NEJMoa041884"}],"container-title":["Journal of Cutaneous Medicine and Surgery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/journals.sagepub.com\/doi\/pdf\/10.1007\/s10227-005-0110-7","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T23:23:15Z","timestamp":1736378595000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10227-005-0110-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,12]]},"references-count":67,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2005,12]]}},"alternative-id":["110"],"URL":"https:\/\/doi.org\/10.1007\/s10227-005-0110-7","relation":{},"ISSN":["1203-4754","1615-7109"],"issn-type":[{"type":"print","value":"1203-4754"},{"type":"electronic","value":"1615-7109"}],"subject":[],"published":{"date-parts":[[2005,12]]}}}